Table 3.
Univariate and multivariate analysis of overall survival in patients with CRC.
| Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|
| Variables | HR (95% CI) | P | HR (95% CI) | P |
| Sex (male vs. female) | 1.471 (0.607–3.565) | 0.393 | ||
| Age (≥ 60 vs. < 60) | 0.918 (0.364–2.316) | 0.857 | ||
| Primary tumor (right- vs. left-sided colon vs. rectum) | 0.747 (0.440–1.268) | 0.280 | ||
| Histology (poorly vs. well/moderate) | 1.738 (0.760–3.974) | 0.190 | ||
| T stage (4 vs. 3, 2, 1) | 1.770(0.792–3.954) | 0.164 | ||
| N stage (2 vs. 1 vs. 0) | 1.351 (0.755–2.415) | 0.311 | ||
| TNM stage (III, IV vs. II) | 1.350 (0.551–3.304) | 0.511 | ||
| Chemotherapy regimen (CAPOX, Capecitabine vs. FOLFOX) | 0.631(0.270–1.474) | 0.287 | ||
| Duration of chemotherapy (> 20 weeks vs. < 20 weeks) | 0.469 (0.208–1.057) | 0.068 | 0.535 (0.236–1.211) | 0.133 |
| Treatment (CIK vs. control) | 0.308 (0.122–0.776) | 0.013a | 0.334 (0.132–0.846) | 0.021a |
HR, Hazard ratio; CI, confidence interval; CRC, colorectal cancer; CAPOX, Capecitabine + Oxaliplatin; FOLFOX, Oxaliplatin + 5-fluorouracil; CIK, cytokine-induced killer cell.
aP value < 0.05